Johnson John

SEC CIK: 0001410781

SEC filings (opens in a new tab)

In the past year, 4 open-market sale filings worth $2.94M and no purchases.

Current role at each company

AXGN Axogen, Inc.Directoras of Jun 26, 2026
XERS Xeris Biopharma Holdings, Inc.Directoras of Jun 5, 2026
VSTM Verastem, Inc.Directoras of May 26, 2026
APLT Applied Therapeutics, Inc.Executive Chairmanas of Dec 20, 2024
SBBP Strongbridge Biopharma plcChief Executive Officeras of Oct 6, 2021

Open-market trades in the past year

Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.

Bought: –; 0 filings
Sold: $2.94M; 4 filings
Net: −$2.94M; Bought minus sold
Companies: 2; With open-market trades

Trades

Every Form 4 that lists Johnson John as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.

Transaction type

Role

Minimum value (USD)

Filed from

Filed to

Filing delay at least (days)

Filing delay at most (days)

XERS Xeris Biopharma Holdings, Inc.

Director3 trades

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Jun 5, 2026 (view filing)	Jun 4	1 day	Johnson JohnDirector	SSale	−15.0K	$6.09	−$91.3K	−2.1%683.1K after	10b5-1
Dec 19, 2025 (view filing)	Dec 19	Same day	Johnson JohnDirector	SSale	−135.4K	$7.22	−$977.6K	−16.2%698.1K after
Aug 15, 2025 (view filing)	Aug 13	2 days	Johnson JohnDirector	SSale	−107.5K	$7.32	−$786.9K	−11.4%833.5K after

AXGN Axogen, Inc.